Literature DB >> 18435416

Identifying the differential effects of silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells.

Gagan Deep1, Nicholas H Oberlies, David J Kroll, Rajesh Agarwal.   

Abstract

Prostate cancer (PCa) is the leading cause of cancer-related deaths in men; urgent measures are warranted to lower this deadly malignancy. Silymarin is a known cancer chemopreventive agent, but the relative anticancer efficacy of its constituents is still unknown. Here, we compared the efficacy of 7 pure flavonolignan compounds isolated from silymarin, namely silybin A, silybin B, isosilybin A, isosilybin B, silydianin, isosilydianin, silychristin and isosilychristin, in advanced human PCa PC3 cells. Silybin A, silybin B, isosilybin A, isosilybin B, silibinin and silymarin strongly inhibited the colony formation by PC3 cells (p < 0.001), while silydianin, silychristin and isosilychristin had marginal effect (p < 0.05). Using cell growth and death assays, we identified isosilybin B as the most effective isomer. FACS analysis for cell cycle also showed that silybin A, silybin B, isosilybin A, isosilybin B, silibinin and silymarin treatment resulted in strong cell cycle arrest in PC3 cells after 72 hr of treatment, while the effect of silydianin, silychristin and isosilychristin was marginal (if any). Western blot analysis also showed the differential effect of these compounds on the levels of cell cycle regulators-cyclins (D, E, A and B), CDKs (Cdk2, 4 and Cdc2), CDKIs (p21 and p27) and other cell cycle regulators (Skp2, Cdc25A, B, C and Chk2). This study provided further evidence for differential anticancer potential among each silymarin constituent, which would have potential implications in devising better formulations of silymarin against prostate and other cancers. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18435416     DOI: 10.1002/ijc.23485

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.316


  25 in total

Review 1.  Silybin and the liver: from basic research to clinical practice.

Authors:  Carmela Loguercio; Davide Festi
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

2.  Isosilybin A induces apoptosis in human prostate cancer cells via targeting Akt, NF-κB, and androgen receptor signaling.

Authors:  Gagan Deep; Subhash C Gangar; Nicholas H Oberlies; David J Kroll; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2010-10       Impact factor: 4.784

Review 3.  The strategies to control prostate cancer by chemoprevention approaches.

Authors:  Harold Ting; Gagan Deep; Chapla Agarwal; Rajesh Agarwal
Journal:  Mutat Res       Date:  2014-01-02       Impact factor: 2.433

4.  Inhibition of cyclooxygenase-2 and inducible nitric oxide synthase by silymarin in proliferating mesenchymal stem cells: comparison with glutathione modifiers.

Authors:  Hamidreza Ahmadi-Ashtiani; Abdolamir Allameh; Hosein Rastegar; Masoud Soleimani; Elham Barkhordari
Journal:  J Nat Med       Date:  2011-06-28       Impact factor: 2.343

5.  Increase of phosphatase and tensin homolog by silymarin to inhibit human pharynx squamous cancer.

Authors:  Chin-Hui Su; Li-Jen Chen; Jyh Fei Liao; Juei-Tang Cheng
Journal:  J Med Food       Date:  2013-08-03       Impact factor: 2.786

Review 6.  Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer.

Authors:  Harold Ting; Gagan Deep; Rajesh Agarwal
Journal:  AAPS J       Date:  2013-04-16       Impact factor: 4.009

7.  Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators.

Authors:  Samiha Mateen; Alpna Tyagi; Chapla Agarwal; Rana P Singh; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2010-03       Impact factor: 4.784

8.  Large-scale isolation of flavonolignans from Silybum marianum extract affords new minor constituents and preliminary structure-activity relationships.

Authors:  Arlene Sy-Cordero; Tyler N Graf; Yuka Nakanishi; Mansukh C Wani; Rajesh Agarwal; David J Kroll; Nicholas H Oberlies
Journal:  Planta Med       Date:  2009-11-25       Impact factor: 3.352

9.  Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle.

Authors:  Hanan S Althagafy; Tyler N Graf; Arlene A Sy-Cordero; Brandon T Gufford; Mary F Paine; Jessica Wagoner; Stephen J Polyak; Mitchell P Croatt; Nicholas H Oberlies
Journal:  Bioorg Med Chem       Date:  2013-04-16       Impact factor: 3.641

10.  Mechanistic study of the biomimetic synthesis of flavonolignan diastereoisomers in milk thistle.

Authors:  Hanan S Althagafy; Maria Elena Meza-Aviña; Nicholas H Oberlies; Mitchell P Croatt
Journal:  J Org Chem       Date:  2013-07-22       Impact factor: 4.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.